Reduced Expression of Sarm1 For Use In Cell Therapy
AssigneeEmendoBio Inc.
InventorsRafi EMMANUEL, Michal GOLAN MASHIACH, Rachel DIAMANT
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for adoptive cell therapy or prophylaxis comprising administering SARM1-inhibited or SARM1-inactivated cells to a subject suffering from or determined to be at risk of suffering from a cancer, infection, disease, or disorder.
Claims33
A method for adoptive cell therapy or prophylaxis comprising administering SARM1-inhibited or SARM1-inactivated cells to a subject suffering from or determined to be at risk of suffering from a cancer, infection, disease, or disorder.
A method for inactivating alleles of the sterile alpha and toll/interleukin-1 receptor motif-containing 1 (SARM1) gene in a cell, the method comprising
- introducing to the cell a composition comprising:
- at least one CRISPR nuclease, or a nucleotide molecule encoding a CRISPR nuclease;
- and
- an RNA molecule comprising a guide sequence portion, or a nucleotide molecule encoding the RNA molecule,
- wherein a complex of the CRISPR nuclease and the RNA molecule affects a double strand break in alleles of the SARM1 gene,
- wherein the guide sequence portion comprises 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs:
- 1-13457, and
- wherein the cell is selected from the group consisting of a hematopoietic stem cell (HSC), induced pluripotent stem cell (iPS cell), iPSc-derived cell, natural killer cell (NK), iPS-derived NK cell (iNK), T cell, innate-like T cell (iT), natural killer T cell (NKT), γδ T cell, iPSc-derived T cell, invariant NKT cell (iNKT), iPSc-derived NKT, monocyte, or macrophage.
A composition, method, process, kit, modified cell, or use as characterized by one or more elements disclosed herein.
Dependencies are inferred from the claim text.